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Background: Although a large number of studies have been dedicated to ovarian hyperstimulation syndrome (OHSS)
none gave full embryological and clinical outcomes comparing oocyte trigger with human chorionic gonadotrophin
(HCG) versus with a gonadotrophin-releasing hormone (GnRH) agonist (Buserelin) in cases with suspicious OHSS. The aim
of the present study was thus to analyze 4894 consecutive assisted reproductive treatment cycles to undercover
associated risk factors for development of OHSS, and the effects of the use of Buserelin as ovulation trigger on
embryological and clinical outcomes.
Methods: In the 51 cases that developed OHSS, ovulation trigger was performed with HCG as indicators were
not suspicious for OHSS. These were compared against two types of groups: 71 cases where Buserelin was used
for ovulation induction due to suspicious development of OHSS; and those remaining 4772 cases where ovulation trigger
was currently performed with HCG (control).
Results: Of the cases treated with Buserelin the oocyte maturation rate and the ongoing pregnancy rate were
significantly lower, with higher rates of ectopic pregnancy and newborn malformations, but none developed
OHSS. Of the OHSS cases, 23 needed hospitalization, with no major complications.
Conclusions: Young age, lower time of infertility, lower basal follicle stimulating hormone levels, higher number of
cases with female factor and polycystic ovarian syndrome, high number of follicles and higher estradiol concentrations
were the risk factors found associated with OHSS. Cases with OHSS also presented higher follicle count but the estradiol
levels were within the normal range. It thus remains to develop more strict criteria to avoid all cases with OHSS.
Keywords: Gonadotrophin-releasing hormone agonist, ICSI, IVF, Ovarian hyperstimulation syndrome, Embryological,
Clinical and newborn outcomesBackground
Ovarian hyperstimulation syndrome is an excessive re-
sponse to controlled ovarian hyperstimulation during treat-
ment cycles by assisted reproduction technologies (ART),
either using in-vitro fertilization (IVF) or intracytoplasmic
sperm injection (ICSI), being the most important iatrogenic
complication of the treatment stimulation protocol [1, 2].* Correspondence: msousa@icbas.up.pt
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creativecommons.org/publicdomain/zero/1.0/During ART treatments, controlled ovarian stimula-
tion leads to multiple oocytes and supra-physiological
levels of estrogens. The presence of OHSS is character-
ized by enlargement of the ovaries associated with asci-
tes due to an increased peritoneal capillary permeability
[3]. It presents a very broad spectrum of clinical mani-
festations, with a incidence of 0.2-1 % of all stimulation
cycles, from mild to moderate symptoms (about 3-6 %
of the ART treatment cycles), which only requires vigi-
lance [2], to more severe symptoms (about 1 % of the
treatment cycles) that often requires hospitalization [4].
Severe OHSS may be associated with hepatic and re-
spiratory failure [2], and with an increased risk of venousicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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severe outcomes, the recognition of risk factors for the
development of OHSS became crucial. These have been
postulated to rely on young age, low body mass index
(BMI), presence of polycystic ovarian syndrome (PCOS),
high basal anti-Mullerian hormone (AMH) concentrations,
high number of antral follicles, development of multiple fol-
licles, number of collected oocytes, high serum estradiol
(E2) levels, blood group A, mutations in bone morphogenic
protein (BMP) alleles, presence of follicle stimulating hor-
mone (FSH) receptor mutations and polymorphisms, high
FSH dosage, high ratio between luteinizing hormone (LH)/
FSH, high human chorionic gonadotrophin (HCG) dosage,
high inhibin A and inhibin B values, high vascular endothe-
lial growth factor (VEGF) and other interleukins levels, de-
creased alpha-2-macroglobulin (inhibitor of VEGF) levels,
and allergies [1–4, 10–12]. Presently, the main risk factors
used to precociously identify the risk of developing OHSS
are the presence of PCOS, the number of developed folli-
cles, and the rising levels of E2 concentrations. The use of a
GnRH agonist as ovulation trigger has been advocated to
avoid OHSS completely [13–15]. Nevertheless, OHSS can
develop at a later stage, as there are cases that evade diag-
nosis. A personalization of the stimulation protocols are
thus of the utmost importance [12].
In the present work we retrospectively analyzed 4894
ART treatment cycles to evaluate the risks for develop-
ment of OHSS. For this, patient demographic and stimu-
lation features, embryological and clinical data were
evaluated. The use of a GNRH agonist as ovulation trig-
ger was also evaluated to analyze its effects on embryo-
logical and clinical outcomes.
Methods
In accordance to the National law on Medical Assisted
Procreation (Law n.° 32/2006, 26 July) and the requisites
of the National Council on Medical Assisted Procreation
(CNPMA, 2008), data bases were used after patient in-
formed and written consent.
Participants
We performed a retrospective analysis of 4894 ART con-
secutive treatment cycles (from 2005 to 2011). Cases that
developed OHSS in which ovulation trigger was performed
with HCG as the monitoring indicators (serum levels of
E2 ≤ 4000 pg/ml; ≤ 20 follicles) were not suspicious for the
development of OHSS, were compared against two types of
groups: those where a GnRH agonist (Buserelin) was used
for ovulation induction due to suspicious development of
OHSS; and those remaining cycles where ovulation trigger
was currently performed with HCG (control). In all OHSS
cases development of symptoms and signs only occurred
after pregnancy confirmation (late OHSS). Also, in all cases,
none of the patients in the three groups had previousOHSS, which helped to exclude this as a potential risk fac-
tor as previously reported [2, 4, 16]. Data on patient demo-
graphic and stimulation characteristics, and embryological
and clinical outcomes were evaluated. No significant differ-
ences were found regarding patient karyotypes.
OHSS classification
Mild OHSS is characterized by the presence of increased
weight, thirst, abdominal discomfort and/or distension,
with an ovary volume of < 5 cm. Moderate OHSS is charac-
terized by the additional presence of nausea and vomiting,
painful abdominal distension, dyspnea and/or ascites
(detectable by ultrasound), with an ovary volume of
5–12 cm, without need for hospitalization. Severe OHSS is
characterized by the presence of vomiting (sometimes un-
controllable), dyspnea, accumulation of fluid in the third
space with hydrothorax and/or tense ascites (with pain)
with evidence of intravascular fluid loss, hypovolemia with
hemoconcentration, electrolyte imbalance, oliguria and/or
hepatorenal failure, with an ovary diameter > 12, with need
for hospitalization [17, 18].
Stimulation protocol
Women underwent controlled ovarian hyperstimulation
with a GnRH antagonist (cetrorelix; Merck Serono, Geneve,
Switzerland; ganirelix; Organon, Oss, Netherlands) short
protocol. For stimulation, recombinant FSH (rFSH) was
used (Puregon; Organon; Gonal-F; Merck Serono). About
36 h before oocyte recovery HCG (5000-10,000 IU, im/sc;
Pregnyl; Organon) or Buserelin (0.8 cc; Suprefact; Sanofi
Aventis, Frankfurt, Germany) were administered. Estradiol
serum levels were assayed at the day or one day before
HCG or GnRH agonist administration [19, 20].
Gamete and embryo handling
Gamete and embryo handling was performed with media
from Medicult (Jyllinge, Denmark) or Vitrolife (Kungsbacka,
Sweden). Microinjection was performed in an inverted
microscope (Nikon DIAPHOT 200; Nikon, Tokyo,
Japan), equipped with a thermal plate (37 °C), Hoffman op-
tics (Nikon) and Narishige micromanipulators (MO-188;
Narishige, Tokyo, Japan), using micropipettes from Swemed
(Goteborg, Sweden). ICSI was performed using the strong
dislocation of the cytoplasm [21]. Embryo grade was evalu-
ated according to described methods [22, 23]. Embryo
transfer was performed under ultrasonography, using a
Sure View Wallace Embryo Replacement Catheter or
Wallace malleable stylet (Smiths Medical Int, Kent, UK).
Luteal supplementation
All patients had luteal supplementation with intravaginal
administration of 200 mg of natural-micronized progester-
one, 8/8 h (600 mg day) (Jaba, Besins Int, Montrouge,
France) beginning on the day of oocyte retrieval.
Sousa et al. Reproductive Biology and Endocrinology  (2015) 13:66 Page 3 of 9Implantation was confirmed by a rise in serum βHCG
12 days after embryo transfer. Progesterone was maintained
until βHCG serum assay and, if positive, it was continued
until 12 weeks of gestation. Clinical pregnancy was
established by ultrasound visualization at 7 weeks of
gestation of a gestational sac. Where a GnRH agonist
was used for triggering final oocyte maturation, luteal
support was associated with one oral tablet of 2 mg es-
tradiol (Isdin, Novo Nordisk, Bagsvaerd, Denmark), 12/
12 h for the same time of progesterone [24].
Statistical analysis
Statistical analysis was carried out through the IBM SPSS
Statistics 20 program for Windows. Means were compared
by the t-Test for independent samples. Categorical variables
were analysed using descriptive statistics and Chi-square
test, with continuity correction. In some variables, in the
presence of cells with expected < 5 value in contingency
tables, the Fisher exact Test was used. Ratios were cal-
culated using the Z-test for population proportions. All
statistical tests were two-tailed, with significance level
of 0.05 (p < 0.05).
Results
Of the 4894 ART treatments analysed, there were 71/
4894 (1.5 %) cycles with a suspection for development of
OHSS and thus Buserelin was used for ovulation trigger,
and all these cases have not developed OHSS. However,
51/4894 (1.0 %) cases evaded OHSS diagnosis and ovula-
tion trigger was performed with HCG. These developed
late OHSS, 28 (28/4894: 0.6 %; 28/51: 54.9 %) of moder-
ate and 23 (23/4894: 0.5 %; 23/51: 45.1 %) of severe in-
tensity, with the later requiring hospitalization. As all
OHSS cases correspond to pregnant women they pre-
sented significant higher rates of implantation, preg-
nancy (biochemical, clinical and ongoing), live birth
delivery (LBDR) and newborn (NB). Nevertheless the
embryological and clinical results of these cases are pre-
sented for comparisons and in Tables.
Male and female ages (Table 1) were significant lower in
the Buserelin and OHSS groups than the control group,
with no differences between the Buserelin and OHSS
groups. There was a significant lower time of infertility
and a higher proportion of female factor in the Buserelin
group in relation to the control group, with no differences
between the control and OHSS groups or between the
Buserelin and OHSS groups. Lower basal FSH (bFSH)
levels were significantly lower in the Buserelin group re-
garding the control and OHSS groups, with no differences
between control and OHSS groups. Cases with PCOS
were significantly higher in the Buserelin group than in
the control and OHSS groups, with the OHSS group be-
ing also significantly higher than the control group. Of the
51 OHSS cases, 15 had PCOS, 8 in the 28 cases withmoderate OHSS (28.6 %) and 7 in the 23 cases with severe
OHSS (30.4 %). The number of follicles was significantly
higher in the Buserelin group than in control and OHSS
groups, with the OHSS group being also significantly
higher than the control group. As expected the total go-
nadotrophin dose was significantly lower in the Buserelin
group regarding control and OHSS groups, with no differ-
ences between control and OHSS groups. The E2 serum
levels were significantly higher in the Buserelin group re-
garding control and OHSS groups, being similar between
the control and OHSS groups. No significant differences
were observed regarding BMI or HCG dose (Table 1).
The mean number of retrieved oocytes (Table 2) was
significantly higher in the Buserelin group than in con-
trol or OHSS groups, with the OHSS group being also
significantly higher than the control group. However, the
oocyte maturation rate was significantly lower in the
Buserelin group, with no differences between the OHSS
and control groups or between the Buserelin and OHSS
groups. The fertilization rate was significantly higher in
the OHSS group, with no differences with the Buserelin
group. No significant differences were observed regard-
ing the embryo cleavage rate and the mean number of
embryos transferred. The rates of biochemical pregnancy
and clinical pregnancy, and of implantation, were signifi-
cantly higher in the OHSS group, with no significant dif-
ferences between the Buserelin and control groups. No
significant differences were found regarding the rates of
twin pregnancies and triplet pregnancies, as well as in
abortion. However, the Buserelin group evidenced a sig-
nificant lower rate of singleton pregnancies in compari-
son with the control group, with no differences between
the control and OHSS groups or between the Buserelin
and OHSS groups. There was a significant higher rate of
ectopic pregnancies in the Buserelin group regarding
both OHSS and control groups, with no differences be-
tween the control and OHSS groups. The ongoing preg-
nancy rate was significantly higher in the OHSS group
and significantly lower in the Buserelin group. The rates
of delivery, LBDR and NB were significantly higher in
the OHSS group regarding both control and Buserelin
groups, with no differences between control and Busere-
lin groups. There were no significant differences in rela-
tion to the sex ratios. There was a significant higher rate
of major NB malformations in the Buserelin group (two
twins, each one with one NB with a major malformation:
Kabuki syndrome and cardiac hypoplasia with surgery),
with no cases of NB malformations in the OHSS group.
The Buserelin and OHSS groups did not present any
case of stillbirths, NB chromosome abnormalities or
early neonatal death (Table 2).
There were no significant differences concerning the
gestational age and NB weight (Table 3). There was 1
case of extremely preterm in the OHSS group, without
Table 1 Demographic and stimulation characteristics
Parameters HCG Buserelin OHSS p
Cycles 4772 71 51
Female age 34.8 ± 4.5 32.3 ± 3.8 32.8 ± 3.5 a,b
Male age 36.6 ± 5.7 34.0 ± 4.1 34.1 ± 4.3 a,b
Time infertility 3.9 ± 3.1 3.1 ± 1.9 3.3 ± 2.2 a
Male factor 58.9 51.7 51.1 NS
Female factor 11.9 27.6 17.0 a
Mixed factors 29.2 20.7 31.9 a
bFSH 7.1 ± 3.1 5.7 ± 2.7 7.5 ± 3.7 a,c
PCOS 6.2 57.7 29.4 a,b,c
BMI 22.4 ± 3.7 22.1 ± 4.3 22.1 ± 4.4 NS
Follicles 6.1 ± 3.5 24.8 ± 8.8 18.1 ± 6.7 a,b,c
Total dose 2008.9 ± 986.3 1266. 1 ± 515.4 1716.2 ± 1000.6 a,c
Time stimulation 8.5 ± 1.7 8.3 ± 1.8 8.1 ± 1.3 NS
Estradiol 1238.3 ± 737.0 3565.9 ± 2592.9 1159.9 ± 711.9 a,c
HCG dose 9411.6 ± 1569.0 - 9482.8 ± 1549.7 NS
Buserelin dose - 0.8 ± 0.0 -
Values in “n”, rate or mean ± SD
Significance (p < 0.05)
a: HCG vs Buserelin
b: HCG vs OHSS
c: Buserelin vs OHSS
NS: not significant
HCG: group of patients without OHSS and oocyte trigger with HCG
Buserelin: group of patients without OHSS and oocyte trigger with Buserelin
OHSS: group of patients with OHSS and oocyte trigger with HCG
Female and male ages, Time of infertility, Male factor, Female factor and Mixed factors (years)
bFSH: basal FSH (mIU/ml)
PCOS: polycystic ovarian syndrome
BMI: body max index
Total dose: Total gonadotrophin dose (IU/ml)
Time of stimulation (days)
Estradiol at HCG day (pg/ml)
HCG dose (IU/ml)
Buserelin dose (IU/ml)
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both the Buserelin and OHSS groups there were no
cases of very low weight (Table 3).
With regard to the 23 severe OHSS cases, the average
hospital stay was of 8.2 days (2–15). All patients presented
at entry bloating and abdominal discomfort, nausea, fatigue
and dyspnea. Blood tests showed hemoconcentration and
ultrasound revealed ovarian enlargement (right ovary:
7.89 cm, 5.5-10 cm; Left ovary: 6.9 cm, 6.3-8.2 cm), with
moderate to massive ascites. This made a diagnosis of late
(after positive βHCG) and severe OHSS. Patients received
fluid therapy (to lower hemoconcentration), furosemide
(to force diuresis, as fluid therapy increases the risk of
ascites and pleural effusion and OHSS is associated
with increased vascular permeability; also, an increased
intra-abdominal pressure can also compress kidneys
and impair renal function), and enoxaparin (due to risk
of thromboembolism derived from hemoconcentration).
The bladder was probed with flowmeter for registration ofdiuresis (most women had some difficulty in urinating on
entry), and a record was made up of the hydroelectrolytic
balance. During hospitalization, patients had no further
complications, and paracentesis or culdocentese were not
necessary. Patients were discharged with indication for rest,
fluid restriction, proper diet, paracetamol (SOS), and imme-
diate referral if they had any signs or symptoms of worsen-
ing situation, which did not occur.
Discussion
Ovarian hyperstimulation syndrome has been reported to
occur in about 0.2-2.6 % of ART treatment cycles [4, 25].
Previous reports evidenced 0.7 % of moderate and 0.3 % of
severe OHSS [26], whereas others reported 2.1 % of severe
OHSS, with 1.2 % of early and 0.9 % of late onset [10]. Our
results are in accordance with these later values as of 4894
ART treatment cycles we had 1.5 % of cases with suspected
OHSS that was efficiently avoided with the use of a GnRH
agonist for ovulation trigger, and 1 % of cases with late
Table 2 Embryological and clinical outcomes
Parameters HCG Buserelin OHSS p
Cycles 4772 71 51
COC 36768 1134 563
COC (mean) 7.8 ± 4.7 16.0 ± 6.9 11.0 ± 4.0 a,b,c
MII 30872 910 469
Maturation rate (MII/COC) 84.0 80.2 83.3 a
2PN/2 PB 21410 648 346
Fertilization rate (2PN/MII) 69.4 71.2 73.8 b
Embryos cleaved 20954 641 337
Embryo cleavage rate (d2/2PN) 97.9 98.9 97.4 NS
Embryo transfer cycles (ETC.) 4391 67 51
n° Embryos transferred (mean) 8443-1.9 ± 0.5 121-1.8 ± 0.4 92-1.8 ± 0.4 NS
Biochemical pregnancy (/ETC.) 1973-44.9 32-47.8 49-96.1 b,c
Clinical pregnancy (CP) (/ETC.) 1709-38.9 20-29.9 48-94.1 b,c
Sacs 2155 23 64
Implantation rate (sacs/n°ET) 25.5 19.0 69.6 b,c
Singletons (/CP) 1197-70.0 9-45.0 29-60.4 a
Twins (/CP) 473-27.7 7-35.0 16-33.3 NS
Triplets (/CP) 11-0.6 0 1-2.1 NS
Ectopic pregnancy (/CP) 28-1.6 4-20.0 2-4.2 a,c
Abortion (/CP) 253-14.8 2-10.0 6-12.5 NS
Ongoing pregnancy (/ETC.) 1428-32.5 14-20.9 40-78.4 a,b,c
Delivery (/ETC.) 1329-30.3 14-20.9 40-78.4 b,c
Stillbirths (/ETC.) 1-0.02 0 0 NS
Live-birth delivery rate (/ETC.) 1328-30.2 14-20.9 40-78.4 b,c
Newborn (NB) (/ETC.) 1655-37.7 19-28.4 53-100 b,c
Male (/NB) 832-50.5 11-57.9 25-47.2 NS
Female (/NB) 817-49.5 8-42.1 28-52.8 NS
Male/Female ratio 1.0 1.4 0.90 NS
Newborn malformations (/NB) 36-2.2 2-10.5 0 a,c
Major (/NB) 27-1.6 2-10.5 0 a,c
Minor (/NB) 9-0.5 0 0 NS
NB Chromosome abnormalities (/NB) 5-0.3 0 0 NS
Early neonatal death (/ETC.) 4-0.1 0 0 NS
Values in “n”, rate or mean ± SD
Significance (p < 0.05)
a: HCG vs Buserelin
b: HCG vs OHSS
c: Buserelin vs OHSS
NS: not significant
HCG: group of patients without OHSS and oocyte trigger with HCG
Buserelin: group of patients without OHSS and oocyte trigger with Buserelin
OHSS: group of patients with OHSS and oocyte trigger with HCG
COC: cumulus-oocyte complexes (aspirated oocytes)
MII: mature oocytes at metaphase II of meiosis
2PN/2 PB: normal fertilized oocytes (with 2 pronuclei and 2 polar bodies)
Sousa et al. Reproductive Biology and Endocrinology  (2015) 13:66 Page 5 of 9onset OHSS, of which 0.6 % were of moderate and 0.5 % of
severe intensity.
Lower female age was associated with OHSS [1, 2, 10,
11, 27] and suggested to be related with a larger numberof recruitable follicles and a higher density of gonado-
trophin receptors, thus enabling a more marked re-
sponse to the same. We also found that a lower female
age was associated with OHSS and this might be related
Table 3 Newborn outcomes
Parameters HCG Buserelin OHSS p
Cycles 4772 71 51
ETC. 4391 67 51
Newborn 1655-37.7 1928.4 53-100 b,c
Gestation age (weeks) 37.4 ± 2.7 38.1 ± 2.4 37.3 ± 2.7 NS
Term 38.5 ± 1.1 39.3 ± 1.6 38.4 ± 1.2 a
Preterm (PT) 33.7 ± 3.0 35.1 ± 1.3 33.3 ± 2.6 NS
Very PT 28.7 ± 2.5 (0) 27.0 (1) a
Extremely PT 25.1 ± 1.7 (0) 27.0 (1) a
Weight (g) 2709.0 ± 705.6 2717.4 ± 693.0 2529.6 ± 726.4 NS
Normal weight 3086.1 ± 352.2 3127.3 ± 570.9 3078.6 ± 379.7 NS
Low weight (LW) 1900.4 ± 507.3 2073.3 ± 160.1 1914.8 ± 485.6 NS
Very LW 1048.6 ± 280.5 (0) 1193.7 ± 261.5 a,c
Extremely LW 756.0 ± 193.2 (0) 861.0 ± 66.5 (2) a
Values in “n” and mean ± SD
Significance (p < 0.05)
a: HCG vs Buserelin
b: HCG vs OHSS
c: Buserelin vs OHSS
NS: not significant
(0), (1) and (2): number of cases
HCG: group of patients without OHSS and oocyte trigger with HCG
Buserelin: group of patients without OHSS and oocyte trigger with Buserelin
OHSS: group of patients with OHSS and oocyte trigger with HCG
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with risk for developing OHSS, although another report
did not find any significant difference regarding bFSH
[28]. However, female age is considered unsuitable as
predictive factor since no cut-off value was still defined
[4, 16, 28]. Although not previously referred, we ob-
served a similar association of OHSS with a lower male
age and time of infertility, which might be associated
with the younger age of the couples.
We observed a significant higher number of female
factor cases in association with the risk of OHSS devel-
opment that might be associated with the increased rate
of PCOS cases (58 %). Although infertility causes have
not been related to OHSS [10], PCOS is one factor
clearly associated with predisposition for developing
OHSS. The predisposition of PCOS patients to OHSS is
probably due to the fact that the higher antral follicle
pool has an increased sensitivity to gonadotropin stimu-
lation [1, 2, 4, 10, 11, 27, 29].
Contrary to previous reports that found an association
between decreased BMI and development of OHSS
[1, 2, 11, 16, 27], we and other authors [4, 10, 28, 30]
did not find a significant difference.
The presence of a large number of developing follicles
has been considered a risk factor for OHSS [1, 10, 11, 27].
However, due to the discrepancies in different studies, even
this parameter is per-se not considered convincing [4]. A
fundamental work suggested a solution to this problemindicating two cut-offs, one when there were ≥ 13 follicles
with ≥ 11 mm, which presented 85.5 % of sensitivity and
69 % of specificity, and the other for E2 concentration
levels > 2560 pg/ml, which presented 53 % of sensitivity and
77 % of specificity. In cases where controlled ovarian hyper-
stimulation is performed with a GnRH antagonist these
values were incremented to > 18 follicles and E2 concentra-
tion levels > 5000 pg/ml, with 83 % of sensitivity and 84 %
of specificity [10]. In the present work, ovarian stimulation
was performed with a GnRH antagonist and in all cases
where Buserelin was used for ovulation trigger the mean
number of follicles was 24.8 ± 8.8 and the mean E2 concen-
tration levels was 3565.9 + 2592.9. However, in our cases
that developed late onset OHSS after HCG being used for
ovulation induction the mean number of follicles was above
(18.1 ± 6.7) the proposed cut-off for follicles, but the mean
E2 levels were below (1159.9 ± 711.9) the suggested cut-off.
The number of collected oocytes has also been sug-
gested to be related with OHSS, but the suggested cut-off
of ≥ 20 oocytes is disputable [4, 10]. Our present results
showed that OHSS can develop even with a mean number
of collected oocytes of 11.0 ± 4.0, although those cases
with suspected risk for OHSS presented a mean number
of 16.0 ± 6.9.
Regarding the total gonadotrophin dose, the time of
stimulation and the HCG dose, we did not observe any re-
lationship to OHSS, which is in accordance with previous
observations [10, 28]. The young age of the ovaries with
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implicated to explain the high levels of E2 observed, with
E2 having been considered the best defined predictor for
OHSS [1, 2, 10, 11, 27, 28]. However, with the use of a
GnRH antagonist for ovarian stimulation, E2 concentra-
tions became less reliable for OHSS prediction [4, 10]. In
our ovarian stimulation we used the antagonist protocol
and previous reports have demonstrated that this protocol
results in a lower number of OHSS cases [31], which reas-
sures our stimulation strategy. A possible explanation for
these findings is that the antagonist largely reduces the dur-
ation of the GnRH analogue and prevents events related to
the flare-up or down-regulation induced by agonists. It also
requires less amounts of FSH, and the E2 production per
follicle and the E2 concentration before HCG administra-
tion is also lower [32]. Thus, although mean E2 concentra-
tions are significantly higher in patients who develop
OHSS, the maximum value alone is not a sufficient accur-
ate predictive factor [4, 10]. Our results thus suggest the
same, as our 51 cases that developed OHSS had similar
mean levels of E2 concentrations (1159.9 ± 711.9 pg/ml) to
those observed in our control group (1238.3 ± 737.0
pg/ml), which means that the suggested E2 levels above
3500–6000 pg/ml to be predictive for OHSS development
[4, 10] are not sufficiently accurate.
Taking all these factors into consideration, it was sug-
gested that the best way to predict development of
OHSS was to combine several factors, such as: E2 con-
centration levels > 4500 pg/ml), number of follicles ≥ 13
with ≥ 11 mm, and oocytes collected > 15). With the use
of a GnRH antagonist for controlled ovarian hyperstimu-
lation these values were suggested to raise to E2 concen-
tration levels of > 5000 pg/ml and to a number of
follicles > 18. However, even with these cut-off values it
has not been possible to totally avoid development of
OHSS [4, 10, 11]. Our results suggest the same, as in
our 51 cases that developed OHSS, the mean E2 concen-
trations were below the referred < 1200 pg/ml, the mean
number of follicles was 18.1 ± 6.7 and the mean number
of retrieved oocytes was 11.0 ± 4.0.
The use of an agonist instead of HCG for ovulation in-
duction can lead to elimination of OHSS [13–15, 24].
However, as it causes corpus luteum deficiency and a de-
fective luteal phase of the endometrium (reduced en-
dogenous progesterone production and low LH
secretion around the time of implantation), the luteal
phase is supplemented with oral E2 besides vaginal pro-
gesterone. Later, it was suggested further supplementa-
tion with a bolus of low dose HCG at oocyte pick-up
[13, 28]. As LH is responsible for the steroidogenic activ-
ity of the corpus luteum, up-regulation of several factors
involved in implantation and activation of endometrial
LH receptors, this HCG bolus finally rescued the luteal
phase [13, 28]. As an alternative, after avoiding OHSSwith the use of an agonist trigger, the fresh embryo
transfer is canceled and all oocytes or embryos are fro-
zen. In a later cycle, with a suited prepared endomet-
rium or in a natural cycle, embryos are thawed and
transferred [15]. Although two cases of severe OHSS
have been described after agonist trigger, the authors
speculated whether GnRH receptor, FSH receptor or LH
receptor gene mutations have led to and OHSS predis-
position [33].
Our results refer to a period where the use of a GnRH
agonist for ovulation trigger was still performed without
a bolus of HCG at ovum pick-up for luteal supplementa-
tion. Nevertheless, we believe that it would be important
to report that in the absence of that type of supplemen-
tation the embryological, clinical and NB outcomes were
not compromised.
There is only one previous study evaluating similar out-
comes, although without providing all parameters that we
present in this report. In that study, 152 patients were
treated with a GnRH agonist for ovulation trigger, followed
by a HCG bolus at oocyte pick-up for luteal rescue, and
compared with 150 patients treated with HCG for ovula-
tion trigger. Comparisons between the two groups did not
show any significant differences towards the rates of oocyte
maturation, fertilization, biochemical pregnancy, clinical
pregnancy, ongoing pregnancy and delivery, with 2 % of
OHSS cases occurring in the HCG group [28].
Our present results thus represent the first study that
gives full demographic, stimulation, embryological, clin-
ical and NB outcomes comparing ovulation trigger with
HCG vs with Buserelin in cases with suspicious OHSS
without the use of a HCG bolus for luteal rescue. With
the use of a GnRH agonist as a ovulation trigger we ob-
tained lower rates of oocyte maturation (84 % vs 80 %)
and ongoing pregnancy (33 % vs 21 %), but we attained
similar rates regarding fertilization (69 % vs 71.2 %), em-
bryo cleavage (98 % vs 99 %), biochemical (45 % vs
48 %) and clinical ((39 % vs 30 %) pregnancies, implant-
ation (26 % vs 19 %), abortion (15 % vs 10 %), live birth
delivery (30 % vs 21 %) and NB (38 % vs 28 %) rates,
and also with no interference with the gestational age
and weight of NB. Furthermore, our rate of OHSS devel-
opment was 1 %.
However, the use of the GnRH agonist was associated
with significant higher rates of ectopic pregnancy and
major NB malformations. Although our cases treated
with the GnRH agonist did not have any case of OHSS,
the results were probably due to the insufficient quality
of the endometrium (lutein insufficiency with an abnor-
mal endometrium out of the implantation phase) as we
did not use the HCG bolus at ovum pick-up for luteal
supplementation. This may also explain the higher rate
of ectopic pregnancy, as the embryo did not find the ap-
propriate endometrial milieu. Regarding the higher rate
Sousa et al. Reproductive Biology and Endocrinology  (2015) 13:66 Page 8 of 9of NB malformations (two cases) this cannot be attrib-
uted to the GnRH agonist as that was not observed in
the long protocol that uses a GnRH agonist for stimula-
tion. Thus, this rate has to be attributed to the low num-
ber of cases analysed.
Conclusions
We found that young age, lower time of infertility, lower
bFSH, higher female factor and PCOS, and high number
of follicles and of E2 concentration were the risk factors
found associated with OHSS. The elevated serum E2
levels and the number of follicles were used to predict
development of OHSS and in 71 cases Buserelin was
used effectively, with no cases of OHSS. Nevertheless 51
cases evaded this diagnosis and developed late onset
OHSS, with 23 needing hospitalization, although with
no major complications. These later cases also presented
higher follicle count but the E2 levels were within the
normal range. It thus remains to develop more strict cri-
teria to avoid all cases with OHSS as previously sug-
gested [4, 10–13, 15, 24, 26, 28, 34].
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